Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of
adults and up to 15-30% of children. Despite a rising prevalence, effective and safe …

Background The diagnosis of atopic dermatitis (AD) is made using evaluated clinical criteria.
Management of AD must consider the symptomatic variability of the disease. Methods EADV …

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis
(AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still …

Atopic dermatitis (AD) is a chronic inflammatory, relapsing disease of the skin, characterized
by intense pruritus, maculopapular or vesicular erythematous lesions and scaling …

Introduction: There are few long-term effectiveness and safety data for dupilumab in the
treatment of atopic dermatitis (AD). The aim of this study was to evaluate efficacy and safety …

This review focuses on recent literature regarding atopic dermatitis (AD). New insights in
epidemiology, diagnostic criteria, quality of life measures, provocative factors …

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

This post hoc analysis examined SCORing Atopic Dermatitis (SCORAD) outcomes in 471
paediatric patients (children age 6–< 12 years, n= 304; adolescents age 12–< 18 years, n …

Background Dupilumab, a fully human monoclonal antibody against interleukin-4 receptor
alpha, inhibits the signals of interleukin-4 and interleukin-13, and has also shown significant …

Background As an evidence resource for the currently planned European Academy of
Allergy and Clinical Immunology (EAACI) clinical practice guideline “systemic treatment of …